MedTrace Logo

Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans

NCT04893395 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-08-09

No results posted yet for this study

Summary

The purpose of this study is to assess the prevalence of veterans with major depressive disorder (MDD) who are being treated with a medication that has current Clinical Pharmacogenetics Implementation Consortium (CPIC) or Pharmacogenomics Knowledgebase (PharmGKB) actionable recommendations that have a pharmacogenomic variation that impacts the safety or efficacy of the subject medication.

Conditions

  • Pharmacogenetics
  • Depressive Disorder, Major
  • Medication Therapy Management

Interventions

OTHER

Pharmacogenomic Screening

First telehealth appointment: 1. Pharmacogenomics education and informed consent 2. Medical history 3. Sample collection Second telehealth appointment: 1. Results of pharmacogenomic testing 2. Utility and limitations of pharmacogenomic testing 3. Patient-specific potential impacts on current or future medication therapies 4. Answering of patient questions 5. Referral to mental health provider(s) for treatment-specific recommendations

Sponsors & Collaborators

  • Tuscaloosa Veterans Affairs Medical Center

    collaborator FED

  • Auburn University

    lead OTHER

Principal Investigators

  • Kimberly B Lloyd, Pharm.D. · Auburn University

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-04-30
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893395 on ClinicalTrials.gov